everolimus

基本解釋

In the treatment group, everolimus was introduced five weeks posttransplantation.
移植后實驗組大鼠給予依維莫司5周。
Everolimus leads to a prolongation of allograft survival, reduced cell infiltrate in the graft, and prevents tubular atrophy and interstitial fibrosis.
依維莫司能夠延長移植物的存活，減少移植物細胞浸潤，防止小管萎縮及間質纖維化。
In the everolimus group, five of six animals survived for 20 weeks with stable serum creatinine and displayed neither acute cellular rejection nor CAN.
而在依維莫司組，六分之五的大鼠存活超過20周，血肌酐水平平穩(wěn)，且既沒有表現(xiàn)出急性細胞性排斥也沒有CAN表現(xiàn)。
The aim of this study is to evaluate the therapeutic effect of everolimus on cellular and humoral mechanisms of chronic allograft damage in a rat model with sensitized recipients.
該研究的目的在于評估依維莫司對于細胞免疫和體液免疫導致的致敏大鼠腎移植模型慢性移植物腎病的作用。
CONCLUSION: The used rat model offers the opportunity to study the influence of everolimus on the interaction of humoral and cellular mechanisms involved in chronic renal damage.
結論：該大鼠模型研究慢性腎臟破壞體液和細胞機制，并研究依維莫司與其的交互作用。